



Free Writing Prospectus  
Filed Pursuant to Rule 433  
Registration No. 333-145845  
January 15, 2008

## *iPath<sup>®</sup> MSCI India Index<sup>SM</sup> ETN*

**New York, NY** (January 15, 2008) – Reference is made to Barclays announcement dated October 26, 2007 and its supplemental announcements dated November 5, 2007 and December 7, 2007, all relating to the suspension of issuance, sale and lending of iPath<sup>®</sup> Exchange Traded Notes linked to the MSCI India Index<sup>SM</sup> (“iPath India”). Barclays actions in relation to iPath India have been taken in response to the announcement of the Securities Exchange Board of India (“SEBI”) implementing further regulations with respect to derivative instruments linked to Indian equity securities.

Based on subsequent discussions and further clarification with respect to the SEBI regulations, Barclays announces, that with immediate effect, Barclays will resume lending iPath India notes from inventory as available from time to time and as consistent with its normal trading practices. The suspension of issuance and sale from inventory, except for sales from inventory to the extent, but only to the extent, that the iPath India notes have previously been sold and redeemed by Barclays, remain in effect.

As disclosed in the Pricing Supplement relating to the iPath India notes under the caption "Risk Factors-The Market Value of the Securities May be Influenced by Many Unpredictable Factors", the market value of iPath India notes may be influenced by, among other things, the levels of supply and demand for the notes. It is possible that the resumption of lending activity, as described above, may influence the market value of iPath India notes. Barclays continues to believe that the limitations on issuance, sale and lending implemented in response to the SEBI's announcement may cause an imbalance of supply and demand in the secondary market for iPath India notes, which may cause iPath India to trade at a premium or discount in relation to its indicative value. Therefore, any purchase of iPath India notes in the secondary market may be at a purchase price significantly different from their indicative value.

An investment in iPath ETNs involves risks, including possible loss of principal. For a description of the main risks see “Risk Factors” in the applicable prospectus.

Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus and other documents Barclays Bank PLC has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting [www.iPathETN.com](http://www.iPathETN.com) or EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). Alternatively, Barclays Bank PLC will arrange for Barclays Capital Inc. to send you the prospectus if you request it by calling toll-free 1-877-76-iPATH, or you may request a copy from any other dealer participating in the offering.

Barclays Global Investors Services, a subsidiary of Barclays Global Investors, N.A. (“BGINA”), assists in the promotion of the Securities. Barclays Global Investors, N.A. and Barclays Capital Inc. (“BCI”) are affiliates of Barclays Bank PLC.

**iPath ETNs (the "Securities") are unsecured obligations of Barclays Bank PLC and are not secured debt. The Securities are riskier than ordinary unsecured debt securities and have no principal protection.** Risks of investing in the Securities include limited portfolio diversification, trade price fluctuations, uncertain principal repayment, and illiquidity. Investing in the Securities is not equivalent to direct investment in index or index components. The investor fee will reduce the amount of investor return at maturity or on redemption, and as a result, investor may receive less than the principal amount of investment at maturity or upon redemption of Securities even if the value of the relevant index has increased. An investment in iPath ETNs may not be suitable for all investors. There are restrictions on the minimum number of Securities that may be redeemed directly with the issuer as specified in the applicable prospectus. Commissions may apply and there are tax consequences in the event of sale, redemption or maturity of Securities. **Sales in the secondary market may result in significant losses.**

The MSCI indexes are the exclusive property of Morgan Stanley Capital International Inc. ("MSCI"). MSCI and the MSCI index names are service mark(s) of MSCI or its affiliates and have been licensed for use for certain purposes by Barclays Bank PLC. The financial securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such financial securities. The Pricing Supplement contains a more detailed description of the limited relationship MSCI has with Barclays Bank PLC and any related financial securities. No purchaser, seller or holder of this product, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this product without first contacting MSCI to determine whether MSCI's permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI.

© 2008 BGINA. All rights reserved. iPath, iPath ETNs and the iPath logo are registered trademarks of Barclays Bank PLC. All other trademarks, servicemarks or registered trademarks are the property, and used with the permission, of their respective owners.